Scarica l'app Stockscreener
231.04
0.35%
-0.1122
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Coagulation Factor Deficiency Therapeutics Market Size in 7MM - openPR.com
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years - Benzinga
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? - The Motley Fool
RNAi Therapeutics and Technology Market Key Players Analysis - openPR.com
Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Growth Stock to Buy According to Billionaires? - Insider Monkey
High Growth Tech Stocks In US With Potential For Expansion - simplywall.st
Morgan Stanley Lowers Alnylam (ALNY) Price Target Amid Earnings Preview | ALNY Stock News - GuruFocus
Cns Specific Antisense Oligonucleotide Market Is Booming - openPR.com
Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last? - MSN
Market turmoil is tanking biotech M&A and IPOs. Here's the playbook startups will use to survive - Endpoints News
Alnylam at 24th Annual Needham Conference: Strategic Growth in Focus By Investing.com - Investing.com Australia
Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Long Term Growth Stock to Buy According to Billionaires? - Insider Monkey
Is Alnylam Pharmaceuticals Gaining or Losing Market Support? - Benzinga
Primary Hyperoxaluria Market to Expand Significantly by 2034, - openPR.com
H.C. Wainwright maintains $500 target on Alnylam stock By Investing.com - Investing.com UK
Alnylam Pharmaceuticals, Inc. (ALNY) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
Alnylam and Tekmira Restructure Relationship and Settle All Litigation - AOL.com
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference - BioSpace
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States - Yahoo Finance
Rnai Technology Market Generated Opportunities, Future Scope - openPR.com
RNAi Leader Alnylam Reveals Growth Strategy at Major Healthcare Conference - Stock Titan
Mitsubishi UFJ Asset Management Co. Ltd. Grows Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know - Benzinga
Pfizer's $11.6 billion Biohaven buy could spark more biotech deals - MarketScreener
Sanofi adds to hemophilia arsenal with FDA nod for Qfitlia - BioWorld MedTech
Sanofi, Alnylam win first RNAi approval for hemophilia A and B - PharmaLive
Alnylam Pharmaceuticals' Qfitlia Approved by FDA for Hemophilia A, B Treatment - MarketScreener
Stifel cuts Alnylam stock price target to $300 from $345 By Investing.com - Investing.com UK
Scotiabank raises Alnylam stock target to $342, maintains rating By Investing.com - Investing.com UK
Stifel raises Alnylam stock price target to $345 on FDA nod - Investing.com India
Redburn-Atlantic sets $353 target on Alnylam stock with Buy rating - Investing.com India
FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B - BioSpace
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025 - BioSpace
Alnylam Pharmaceuticals (NasdaqGS:ALNY) Celebrates FDA Approval of Qfitlia Despite 5% Share Price Dip - simplywall.st
Groundbreaking HELIOS-B Trial: AMVUTTRA Proves Major Breakthrough for Heart Disease Patients - Stock Titan
Alnylam’s Qfitlia gets FDA nod for hemophilia treatment By Investing.com - Investing.com South Africa
FDA approves first-of-its-kind RNA drug for hemophilia - BioPharma Dive
Alnylam’s Qfitlia gets FDA nod for hemophilia treatment - Investing.com India
Revolutionary Hemophilia Treatment Achieves 90% Bleed Reduction in FDA Approval - Stock Titan
FDA approves Sanofi’s RNAi drug for hemophilia A and B - Endpoints News
Alnylam CEO's compensation package continues to grow - NBC Boston
Alnylam CEO’s compensation package continues to grow - The Business Journals
Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More - Yahoo Finance
Transthyretin Amyloidosis Treatment Market Detailed In New - openPR
Alnylam Pharmaceuticals director David Pyott sells $2.2 million in stock By Investing.com - Investing.com Australia
Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains? - MSN
Alnylam Pharmaceuticals director David Pyott sells $2.2 million in stock - Investing.com India
Alnylam Pharmaceuticals’ SWOT analysis: stock poised for growth in expanding ATTR-CM market - Investing.com India
FDA approves new drug to treat protein buildup in the heart - MSN
1.25%
0.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):